glp 1 for cardiovascular disease GLP-1RAs reduce deaths in patients with CKM comorbidity | Duke Clinical Research Institute posted on the topic JCI - Cardioprotective GLP-1 metabolite

Most adults who have obesity are good candidates for these medications, according to Dr

This approach ensures that GLP-1 therapy is tailored to those most likely to benefit from improved metabolic health, weight reduction, and reduced risk of other health conditions such as cardiovascular issues and blood sugar imbalances

While nausea, vomiting, and diarrhea are common with semaglutide therapy, severe or persistent symptomsparticularly if they differ from your usual experienceshould be evaluated

Jim Justice who has lost between 30 and 50 pounds while taking Ozempic said after Bidens announcement that he would be a proponent of trying to do everything we can to be able to expand these drugs to everybody. Theres a real argument that at the end of the day, we end up saving that money, said Justice, who was elected to the U.S

More than one-half of patients (57.1%) had been taking an SGLT2 inhibitor for at least 1 year (Table 1)